Impact of Vitamin D Supplementation on Arterial Vasomotion, Stiffness and Endothelial Biomarkers in Chronic Kidney Disease Patients

Chitalia, Nihil; Ismail, Tuan; Tooth, Laura; Boa, Frances; Hampson, Geeta; Goldsmith, David; Kaski, Juan Carlos; Banerjee, Debasish
March 2014
PLoS ONE;Mar2014, Vol. 9 Issue 3, p1
Academic Journal
Background: Cardiovascular events are frequent and vascular endothelial function is abnormal in patients with chronic kidney disease (CKD). We demonstrated endothelial dysfunction with vitamin D deficiency in CKD patients; however the impact of cholecalciferol supplementation on vascular stiffness and vasomotor function, endothelial and bone biomarkers in CKD patients with low 25-hydroxy vitamin D [25(OH)D] is unknown, which this study investigated. Methods: We assessed non-diabetic patients with CKD stage 3/4, age 17–80 years and serum 25(OH)D <75 nmol/L. Brachial artery Flow Mediated Dilation (FMD), Pulse Wave Velocity (PWV), Augmentation Index (AI) and circulating blood biomarkers were evaluated at baseline and at 16 weeks. Oral 300,000 units cholecalciferol was administered at baseline and 8-weeks. Results: Clinical characteristics of 26 patients were: age 50±14 (mean±1SD) years, eGFR 41±11 ml/min/1.73 m2, males 73%, dyslipidaemia 36%, smokers 23% and hypertensives 87%. At 16-week serum 25(OH)D and calcium increased (43±16 to 84±29 nmol/L, p<0.001 and 2.37±0.09 to 2.42±0.09 mmol/L; p = 0.004, respectively) and parathyroid hormone decreased (10.8±8.6 to 7.4±4.4; p = 0.001). FMD improved from 3.1±3.3% to 6.1±3.7%, p = 0.001. Endothelial biomarker concentrations decreased: E-Selectin from 5666±2123 to 5256±2058 pg/mL; p = 0.032, ICAM-1, 3.45±0.01 to 3.10±1.04 ng/mL; p = 0.038 and VCAM-1, 54±33 to 42±33 ng/mL; p = 0.006. eGFR, BP, PWV, AI, hsCRP, von Willebrand factor and Fibroblast Growth Factor-23, remained unchanged. Conclusion: This study demonstrates for the first time improvement of endothelial vasomotor and secretory functions with vitamin D in CKD patients without significant adverse effects on arterial stiffness, serum calcium or FGF-23. Trial Registration: ClinicalTrials.gov NCT02005718


Related Articles

  • Vitamin D and Cardiovascular Disease. Gouni-Berthold, Ioanna; Krone, Wilhelm; Berthold, Heiner K. // Current Vascular Pharmacology;Jul2009, Vol. 7 Issue 3, p414 

    Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide. Recently vitamin D deficiency has been identified as a potential risk factor for many diseases not traditionally associated with vitamin D, such as cancer and CVD. This review discusses the evidence suggesting an...

  • Low Vitamin D Raises Death Risk. Tweed, Vera // Better Nutrition;Dec2012, Vol. 74 Issue 12, p12 

    The article discusses research which was published in a 2012 issue of "Arteriosclerosis, Thrombosis, and Vascular Biology" and found that low levels of vitamin D raise the risk of heart attack by 64%, coronary artery disease by 40% and death from heart disease by 81% in humans.

  • B-type natriuretic peptide is an independent predictor of endothelial function in man. PAURIAH, Maheshwar; KHAN, Faisel; LIM, Tiong K.; ELDER, Douglas H.; GODFREY, Valerie; KENNEDY, Gwen; BELCH, Jill J. F.; BOOTH, Nuala A.; STRUTHERS, Allan D.; LANG, Chim C. // Clinical Science;2012, Vol. 123 Issue 5, p307 

    BNP (B-type natriuretic peptide) has been reported to be elevated in preclinical states of vascular damage. To elucidate the relationship between plasma BNP and endothelial function, we have investigated the relationship between BNP and endothelial function in a cohort of subjects comprising...

  • Differential Associations of Inflammatory and Endothelial Biomarkers with Disease Activity in Rheumatoid Arthritis of Short Duration. Klimek, Ewa; Skalska, Anna; Kwaśny-Krochin, Beata; Surdacki, Andrzej; Sulicka, Joanna; Korkosz, Mariusz; Fedak, Danuta; Kierzkowska, Izabella; Wizner, Barbara; Grodzicki, Tomasz K. // Mediators of Inflammation;2014, Vol. 2014, p1 

    Objectives. To estimate endothelial dysfunction in patients with rheumatoid arthritis (RA) of short duration in relation to disease activity based on the assessment of 28 joints (DAS28). Methods. We studied 29 patients (22 women, mean age 41 (SD, 9) years) with RA of short duration and 29...

  • Seasonal vitamin D status and endothelial function in healthcare workers. HALİLOĞLU, Özlem; KASACI, Tolga; YAVUZ, Dilek // Turkish Journal of Medical Sciences;2016, Vol. 46 Issue 1, p72 

    Background/aim: Healthcare workers have long working hours indoors and are at risk of vitamin D deficiency. The aim of this study was to determine seasonal vitamin D status and its relationship with early atherosclerotic markers, endothelial function, and carotid intima-media thickness (CIMT) in...

  • MIDSPAN Family Study: Vitamin D deficiency not linked to CVD. Costa, Samantha; Foster, Melissa // Endocrine Today;Nov2012, Vol. 10 Issue 11, p50 

    The article reports on a study which found that vitamin D deficiency is not associated with an increased risk for cardiovascular disease (CVD).

  • Carotid intima media thickness in adolescents with increased risk for atherosclerosis. Erkoçoğlu, Mustafa; Özön, Z. Alev; Göçmen, Rahsan; Alikaşifoğlu, Ayfer; Gönç, Nazlı; Kandemir, Nurgün // Turkish Journal of Pediatrics;2013, Vol. 55 Issue 5, p510 

    In this study, we aimed to analyze early-onset atherosclerotic changes in adolescents with risk of cardiovascular disease in comparison to healthy controls using carotid intima media thickness (CIMT), homocysteine and markers of endothelial function as indicators. Children aged 10 years or...

  • Pharmacometabolomics of Statin Response. Krauss, R M; Zhu, H; Kaddurah-Daouk, R // Clinical Pharmacology & Therapeutics;Nov2013, Vol. 94 Issue 5, p562 

    Statins reduce risk of cardiovascular disease (CVD) by decreasing plasma low-density lipoprotein (LDL) concentrations, as well as reducing inflammation and improving endothelial function. Despite their documented efficacy, there is considerable interindividual variation in effects of statins on...

  • Asymmetric Dimethyarginine as Marker and Mediator in Ischemic Stroke. Shufen Chen; Na Li; Deb-Chatterji, Milani; Qiang Dong; Kielstein, Jan T.; Weissenborn, Karin; Worthmann, Hans // International Journal of Molecular Sciences;Dec2012, Vol. 13 Issue 12, p15983 

    Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase (NOS) inhibitor, is known as mediator of endothelial cell dysfunction and atherosclerosis. Circulating ADMA levels are correlated with cardiovascular risk factors such as hypercholesterolemia, arterial hypertension, diabetes...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics